Abstract
The incidence of acute and chronic spinal cord injury (SCI) in the United States is more than 10,000 per year, resulting in 720 cases per million persons enduring permanent disability each year. The economic impact of SCI is estimated to be more than 4 billion dollars annually. Preclinical studies, case reports, and small clinical trials suggest that early treatment may improve neurological recovery. To date, no proven therapeutic modality exists that has demonstrated a positive effect on neurological outcome. Emerging data from recent preclinical and clinical studies offer hope for this devastating condition. This review gives an overview of current basic research and clinical studies for the treatment of SCI.
Similar content being viewed by others
References
Bracken MB (2012) Steroids for acute spinal cord injury. Cochrane Database Syst Rev 1:CD001046
Budh CN, Osteraker AL (2007) Life satisfaction in individuals with a spinal cord injury and pain. Clin Rehabil 21(1):89–96
Farooqui (2010) Neurochemical aspects of spinal cord injury. In: Farooqui AA (ed) Neurochemical aspects of neurotraumatic and neurodegenerative diseases. Springer, Berlin, pp 107–142
Kiser TS Predicting outcome (prognosis) in spinal cord injury. In: Comission ASC (ed). http://www.spinalcord.ar.gov/Resources/Prognosis%20Fact%20Sheet.pdf2010.
Dumont RJ, Okonkwo DO, Verma S et al (2001) Acute spinal cord injury, part I: pathophysiologic mechanisms. Clin Neuropharmacol 24(5):254–264
Guly HR, Bouamra O, Lecky FE (2008) The incidence of neurogenic shock in patients with isolated spinal cord injury in the emergency department. Resuscitation 76(1):57–62
Bracken MB, Collins WF, Freeman DF et al (1984) Efficacy of methylprednisolone in acute spinal cord injury. JAMA, J Am Med Assoc 251(1):45–52
Bracken MB, Shepard MJ, Collins WF Jr et al (1992) Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second national acute spinal cord injury study. J Neurosurg 76(1):23–31
Bracken MB, Shepard MJ, Collins WF et al (1990) A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the second national acute spinal cord injury study. New Engl J Med 322(20):1405–1411
Tator CH (2006) Review of treatment trials in human spinal cord injury: issues, difficulties, and recommendations. Neurosurgery 59(5):957–982; discussion 982–957
Chvatal SA, Kim YT, Bratt-Leal AM, Lee H, Bellamkonda RV (2008) Spatial distribution and acute anti-inflammatory effects of methylprednisolone after sustained local delivery to the contused spinal cord. Biomaterials 29(12):1967–1975
Das A, Smith JA, Gibson C, Varma AK, Ray SK, Banik NL (2011) Estrogen receptor agonists and estrogen attenuate TNF-alpha-induced apoptosis in VSC4.1 motoneurons. J Endocrinol 208(2):171–182
Sribnick EA, Wingrave JM, Matzelle DD, Wilford GG, Ray SK, Banik NL (2005) Estrogen attenuated markers of inflammation and decreased lesion volume in acute spinal cord injury in rats. J Neurosci Res 82(2):283–293
Wingrave JM, Schaecher KE, Sribnick EA et al (2003) Early induction of secondary injury factors causing activation of calpain and mitochondria-mediated neuronal apoptosis following spinal cord injury in rats. J Neurosci Res 73(1):95–104
Bains M, Hall ED (2012) Antioxidant therapies in traumatic brain and spinal cord injury. Biochim Biophys Acta 1822(5):675–684
Robert AA, Zamzami M, Sam AE (2012) Al Jadid M, Al Mubarak S. The efficacy of antioxidants in functional recovery of spinal cord injured rats: an experimental study. Neurol Sci 33(4):785–791
Samantaray S, Sribnick EA, Das A et al (2008) Melatonin attenuates calpain upregulation, axonal damage and neuronal death in spinal cord injury in rats. J Pineal Res 44(4):348–357
Mazzone GL, Nistri A (2011) Delayed neuroprotection by riluzole against excitotoxic damage evoked by kainate on rat organotypic spinal cord cultures. Neuroscience 190:318–327
Rong W, Wang J, Liu X et al (2012) 17beta-estradiol attenuates neural cell apoptosis through inhibition of JNK phosphorylation in SCI rats and excitotoxicity induced by glutamate in vitro. Int J Neurosci 122(7):381–387
Lutton C, Young YW, Williams R, Meedeniya AC, Mackay-Sim A, Goss B (2012) Combined VEGF and PDGF treatment reduces secondary degeneration after spinal cord injury. J Neurotrauma 29(5):957–970
Ritz MF, Graumann U, Gutierrez B, Hausmann O (2010) Traumatic spinal cord injury alters angiogenic factors and TGF-beta1 that may affect vascular recovery. Curr Neurovasc Res 7(4):301–310
Ray SK, Matzelle DD, Sribnick EA, Guyton MK, Wingrave JM, Banik NL (2003) Calpain inhibitor prevented apoptosis and maintained transcription of proteolipid protein and myelin basic protein genes in rat spinal cord injury. J Chem Neuroanat 26(2):119–124
Ray SK, Samantaray S, Smith JA, Matzelle DD, Das A, Banik NL (2011) Inhibition of cysteine proteases in acute and chronic spinal cord injury. Neurotherapeutics 8(2):180–186
Sribnick EA, Matzelle DD, Banik NL, Ray SK (2007) Direct evidence for calpain involvement in apoptotic death of neurons in spinal cord injury in rats and neuroprotection with calpain inhibitor. Neurochem Res 32(12):2210–2216
Guha A, Tator CH, Piper I (1987) Effect of a calcium channel blocker on posttraumatic spinal cord blood flow. J Neurosurg 66(3):423–430
Das A, McDowell M, Pava MJ, Smith JA, Reiter RJ, Woodward JJ, Varma AK, Ray SK, Banik NL (2010) The inhibition of apoptosis by melatonin in VSC4.1 motoneurons exposed to oxidative stress, glutamate excitotoxicity, or TNF-alpha toxicity involves membrane melatonin receptors. J Pineal Res 48(2):157–169
Ray SK, Hogan EL, Banik NL (2003) Calpain in the pathophysiology of spinal cord injury: neuroprotection with calpain inhibitors. Brain Res Rev 42(2):169–185
Samantaray S, Sribnick EA, Das A et al (2010) Neuroprotective efficacy of estrogen in experimental spinal cord injury in rats. Ann N Y Acad Sci 1199:90–94
Lee JY, Choi SY, Oh TH, Yune TY (2012) 17beta-estradiol inhibits apoptotic cell death of oligodendrocytes by inhibiting rhoA-JNK3 activation after spinal cord injury. Endocrinology 153(8):3815–3827
Samantaray S, Smith JA, Das A et al (2011) Low dose estrogen prevents neuronal degeneration and microglial reactivity in an acute model of spinal cord injury: effect of dosing, route of administration, and therapy delay. Neurochem Res 36(10):1809–1816
Wang YF, Fan ZK, Cao Y, Yu DS, Zhang YQ, Wang YS (2011) 2-Methoxyestradiol inhibits the up-regulation of AQP4 and AQP1 expression after spinal cord injury. Brain Res 1370:220–226
Bonnefont-Rousselot D, Collin F, Jore D, Gardes-Albert M (2011) Reaction mechanism of melatonin oxidation by reactive oxygen species in vitro. J Pineal Res 50(3):328–335
Wu UI, Mai FD, Sheu JN et al (2011) Melatonin inhibits microglial activation, reduces pro-inflammatory cytokine levels, and rescues hippocampal neurons of adult rats with acute Klebsiella pneumoniae meningitis. J Pineal Res 50(2):159–170
Das A, Wallace IV G, Reiter RJ, et al (2013) Overexpression of melatonin membrane receptors increases calcium-binding proteins and protects VSC4.1 motoneurons from glutamate toxicity through multiple mechanisms. J Pineal Res 54:58–68
Borisoff JF, Chan CC, Hiebert GW et al (2003) Suppression of Rho-kinase activity promotes axonal growth on inhibitory CNS substrates. Mol Cell Neurosci 22(3):405–416
Ferrari G, Fabris M, Gorio A (1983) Gangliosides enhance neurite outgrowth in PC12 cells. Brain Res 284(2–3):215–221
Gonzenbach RR, Schwab ME (2008) Disinhibition of neurite growth to repair the injured adult CNS: focusing on Nogo. Cell Mol Life Sci 65(1):161–176
Gorio A, Ferrari G, Fusco M, Janigro D, Zanoni R, Jonsson G (1984) Gangliosides and their effects on rearranging peripheral and central neural pathways. Cent Nerv Syst Trauma 1(1):29–37
Liu BP, Cafferty WB, Budel SO, Strittmatter SM (2006) Extracellular regulators of axonal growth in the adult central nervous system. Philos Trans R Soc Lond B Biol Sci 361(1473):1593–1610
Schwab ME (2004) Nogo and axon regeneration. Curr Opin Neurobiol 14(1):118–124
Yiu G, He Z (2006) Glial inhibition of CNS axon regeneration. Nat Rev Neurosci 7(8):617–627
Karimi-Abdolrezaee S, Billakanti R (2012) Reactive astrogliosis after spinal cord injury-beneficial and detrimental effects. Mol Neurobiol 46(2):251–264
Dergham P, Ellezam B, Essagian C, Avedissian H, Lubell WD, McKerracher L (2002) Rho signaling pathway targeted to promote spinal cord repair. J Neurosci 22(15):6570–6577
Dubreuil CI, Winton MJ, McKerracher L (2003) Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system. J Cell Biol 162(2):233–243
Jalink K, van Corven EJ, Hengeveld T, Morii N, Narumiya S, Moolenaar WH (1994) Inhibition of lysophosphatidate- and thrombin-induced neurite retraction and neuronal cell rounding by ADP ribosylation of the small GTP-binding protein Rho. J Cell Biol 126(3):801–810
Lord-Fontaine S, Yang F, Diep Q et al (2008) Local inhibition of Rho signaling by cell-permeable recombinant protein BA-210 prevents secondary damage and promotes functional recovery following acute spinal cord injury. J Neurotrauma 25(11):1309–1322
Sung JK, Miao L, Calvert JW, Huang L, Louis Harkey H, Zhang JH (2003) A possible role of RhoA/Rho-kinase in experimental spinal cord injury in rat. Brain Res 959(1):29–38
Gu YL, Yin LW, Zhang Z et al (2012) Neurotrophin expressions in neural stem cells grafted acutely to transected spinal cord of adult rats linked to functional improvement. Cell Mol Neurobiol 32(7):1089–1097
Quertainmont R, Cantinieaux D, Botman O, Sid S, Schoenen J, Franzen R (2012) Mesenchymal stem cell graft improves recovery after spinal cord injury in adult rats through neurotrophic and pro-angiogenic actions. PLoS One 7(6):e39500
Uchida K, Nakajima H, Hirai T et al (2012) The retrograde delivery of adenovirus vector carrying the gene for brain-derived neurotrophic factor protects neurons and oligodendrocytes from apoptosis in the chronically compressed spinal cord of twy/twy mice. Spine 37(26):2125–2135
Donnelly EM, Lamanna J, Boulis NM (2012) Stem cell therapy for the spinal cord. Stem Cell Res Ther 3(4):24
Wang H, Fang H, Dai J, Liu G, Xu ZJ (2013) Induced pluripotent stem cells for spinal cord injury therapy: current status and perspective. Neurol Sci 34(1):11–17
Reddy MK, Wu L, Kou W, Ghorpade A, Labhasetwar V (2008) Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stress. Appl Biochem Biotechnol 151(2–3):565–577
Vertegel AA, Reukov V, Maximov V (2011) Enzyme-nanoparticle conjugates for biomedical applications. Methods Mol Biol 679:165–182
Sharma HS (2008) New perspectives for the treatment options in spinal cord injury. Expert Opin Pharmacother 9(16):2773–2800
Begley DJ (2004) Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther 104(1):29–45
Schroeder U, Sommerfeld P, Ulrich S, Sabel BA (1998) Nanoparticle technology for delivery of drugs across the blood-brain barrier. J Pharm Sci 87(11):1305–1307
Torchilin VP (2000) Drug targeting. Eur J Pharm Sci 11(Suppl 2):S81–91
Kreuter J (2001) Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47(1):65–81
Lin Y, Pan Y, Shi Y, Huang X, Jia N, Jiang JY (2012) Delivery of large molecules via poly(butyl cyanoacrylate) nanoparticles into the injured rat brain. Nanotechnology 23(16):165101
Kreuter J, Ramge P, Petrov V et al (2003) Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 20(3):409–416
Kurakhmaeva KB, Djindjikhashvili IA, Petrov VE et al (2009) Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target 17(8):564–574
Sharma HS, Ali S, Tian ZR et al (2009) Nano-drug delivery and neuroprotection in spinal cord injury. J Nanosci Nanotechnol 9(8):5014–5037
Gibaud S, Demoy M, Andreux JP, Weingarten C, Gouritin B, Couvreur P (1996) Cells involved in the capture of nanoparticles in hematopoietic organs. J Pharm Sci 85(9):944–950
Moghimi SM, Hunter AC (2001) Capture of stealth nanoparticles by the body’s defences. Crit Rev Ther Drug Carrier Syst 18(6):527–550
Kang CE, Baumann MD, Tator CH, Shoichet MS. Localized and sustained delivery of fibroblast growth factor-2 from a nanoparticle-hydrogel composite for treatment of spinal cord injury. Cells Tissues Organs. Jul 13 2012
Cho Y, Shi R, Ivanisevic A, Borgens RB (2010) Functional silica nanoparticle-mediated neuronal membrane sealing following traumatic spinal cord injury. J Neurosci Res 88(7):1433–1444
Wang YT, Lu XM, Zhu F et al (2011) The use of a gold nanoparticle-based adjuvant to improve the therapeutic efficacy of hNgR-Fc protein immunization in spinal cord-injured rats. Biomaterials 32(31):7988–7998
Xia T, Kovochich M, Brant J et al (2006) Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett 6(8):1794–1807
Hall ED, Braughler JM (1982) Glucocorticoid mechanisms in acute spinal cord injury: a review and therapeutic rationale. Surg Neurol 18(5):320–327
Bracken MB, Shepard MJ, Holford TR et al (1998) Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third national acute spinal cord injury randomized controlled trial. J Neurosurg 89(5):699–706
Braughler JM, Hall ED (1983) Lactate and pyruvate metabolism in injured cat spinal cord before and after a single large intravenous dose of methylprednisolone. J Neurosurg 59(2):256–261
Faden AI, Jacobs TP, Mougey E, Holaday JW (1981) Endorphins in experimental spinal injury: therapeutic effect of naloxone. Ann Neurol 10(4):326–332
Coleman WP, Benzel D, Cahill DW et al (2000) A critical appraisal of the reporting of the national acute spinal cord injury studies (II and III) of methylprednisolone in acute spinal cord injury. J Spinal Disord 13(3):185–199
Hurlbert RJ (2001) The role of steroids in acute spinal cord injury: an evidence-based analysis. Spine 26(24 Suppl):S39–46
Qian T, Guo X, Levi AD, Vanni S, Shebert RT, Sipski ML (2005) High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients. Spinal Cord 43(4):199–203
Anderson DK, Braughler JM, Hall ED, Waters TR, McCall JM, Means ED (1988) Effects of treatment with U-74006F on neurological outcome following experimental spinal cord injury. J Neurosurg 69(4):562–567
Fehlings MG, Tator CH, Linden RD (1989) The effect of nimodipine and dextran on axonal function and blood flow following experimental spinal cord injury. J Neurosurg 71(3):403–416
Haghighi SS, Stiens T, Oro JJ, Madsen R (1993) Evaluation of the calcium channel antagonist nimodipine after experimental spinal cord injury. Surg Neurol 39(5):403–408
Ross IB, Tator CH (1991) Further studies of nimodipine in experimental spinal cord injury in the rat. J Neurotrauma 8(4):229–238
Pointillart V, Petitjean ME, Wiart L et al (2000) Pharmacological therapy of spinal cord injury during the acute phase. Spinal Cord 38(2):71–76
Gaviria M, Privat A, d’Arbigny P, Kamenka J, Haton H, Ohanna F (2000) Neuroprotective effects of a novel NMDA antagonist, Gacyclidine, after experimental contusive spinal cord injury in adult rats. Brain Res 874(2):200–209
Gaviria M, Privat A, d’Arbigny P, Kamenka JM, Haton H, Ohanna F (2000) Neuroprotective effects of gacyclidine after experimental photochemical spinal cord lesion in adult rats: dose-window and time-window effects. J Neurotrauma 17(1):19–30
Fehlings MG, Baptiste DC (2005) Current status of clinical trials for acute spinal cord injury. Injury 36(Suppl 2):B113–122
Monga V, Meena CL, Kaur N, Jain R (2008) Chemistry and biology of thyrotropin-releasing hormone (TRH) and its analogs. Curr Med Chem 15(26):2718–2733
Naftchi NE (1982) Prevention of damage in acute spinal cord injury by peptides and pharmacologic agents. Peptides 3(3):235–247
Faden AI, Jacobs TP, Smith MT (1984) Thyrotropin-releasing hormone in experimental spinal injury: dose response and late treatment. Neurology 34(10):1280–1284
Pitts LH, Ross A, Chase GA, Faden AI (1995) Treatment with thyrotropin-releasing hormone (TRH) in patients with traumatic spinal cord injuries. J Neurotrauma 12(3):235–243
Ledeen RW (1978) Ganglioside structures and distribution: are they localized at the nerve ending? J Supramol Struct 8(1):1–17
Sabel BA, Slavin MD, Stein DG (1984) GM1 ganglioside treatment facilitates behavioral recovery from bilateral brain damage. Science 225(4659):340–342
Sabel BA, DelMastro R, Dunbar GL, Stein DG (1987) Reduction of anterograde degeneration in brain damaged rats by GM1-gangliosides. Neurosci Lett 77(3):360–366
Cuello AC, Stephens PH, Tagari PC, Sofroniew MV, Pearson RC (1986) Retrograde changes in the nucleus basalis of the rat, caused by cortical damage, are prevented by exogenous ganglioside GM1. Brain Res 376(2):373–377
Geisler FH, Dorsey FC, Coleman WP (1991) Recovery of motor function after spinal-cord injury–a randomized, placebo-controlled trial with GM-1 ganglioside. New Engl J Med 324(26):1829–1838
Geisler FH, Coleman WP, Grieco G, Poonian D (2001) The Sygen multicenter acute spinal cord injury study. Spine 26(24 Suppl):S87–98
Geisler FH, Coleman WP, Grieco G, Poonian D (2001) Measurements and recovery patterns in a multicenter study of acute spinal cord injury. Spine 26(24 Suppl):S68–86
Geisler FH, Coleman WP, Grieco G, Poonian D (2001) Recruitment and early treatment in a multicenter study of acute spinal cord injury. Spine 26(24 Suppl):S58–67
Chinnock P, Roberts I (2005) Gangliosides for acute spinal cord injury. Cochrane Database Syst Rev 2:CD004444
Fehlings MG, Theodore N, Harrop J et al (2011) A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J Neurotrauma 28(5):787–796
Liebscher T, Schnell L, Schnell D et al (2005) Nogo-A antibody improves regeneration and locomotion of spinal cord-injured rats. Ann Neurol 58(5):706–719
Freund P, Schmidlin E, Wannier T et al (2006) Nogo-A-specific antibody treatment enhances sprouting and functional recovery after cervical lesion in adult primates. Nat Med 12(7):790–792
Zorner B, Schwab ME (2010) Anti-Nogo on the go: from animal models to a clinical trial. Ann N Y Acad Sci 1198(Suppl 1):E22–34
Cheng H, Cao Y, Olson L (1996) Spinal cord repair in adult paraplegic rats: partial restoration of hind limb function. Science 273(5274):510–513
Cheng H, Liao KK, Liao SF, Chuang TY, Shih YH (2004) Spinal cord repair with acidic fibroblast growth factor as a treatment for a patient with chronic paraplegia. Spine 29(14):E284–288
Wu JC, Huang WC, Chen YC et al (2011) Acidic fibroblast growth factor for repair of human spinal cord injury: a clinical trial. J Neurosurg Spine 15(3):216–227
Bomstein Y, Marder JB, Vitner K et al (2003) Features of skin-coincubated macrophages that promote recovery from spinal cord injury. J Neuroimmunol 142(1–2):10–16
Knoller N, Auerbach G, Fulga V et al (2005) Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results. J Neurosurg Spine 3(3):173–181
Schwartz M, Yoles E (2005) Macrophages and dendritic cells treatment of spinal cord injury: from the bench to the clinic. Acta Neurochir 93:147–150
Caplan AI (2007) Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol 213(2):341–347
Sykova E, Homola A, Mazanec R et al (2006) Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant 15(8–9):675–687
Deda H, Inci MC, Kurekci AE et al (2008) Treatment of chronic spinal cord injured patients with autologous bone marrow-derived hematopoietic stem cell transplantation: 1-year follow-up. Cytotherapy 10(6):565–574
Kumar AA, Kumar SR, Narayanan R, Arul K, Baskaran M (2009) Autologous bone marrow derived mononuclear cell therapy for spinal cord injury: a Phase I/II clinical safety and primary efficacy data. Exp Clin Transplant 7(4):241–248
Kishk NA, Gabr H, Hamdy S et al (2010) Case control series of intrathecal autologous bone marrow mesenchymal stem cell therapy for chronic spinal cord injury. Neurorehabil Neural Repair 24(8):702–708
Huard JM, Youngentob SL, Goldstein BJ, Luskin MB, Schwob JE (1998) Adult olfactory epithelium contains multipotent progenitors that give rise to neurons and non-neural cells. J Comp Neurol 400(4):469–486
Li Y, Field PM, Raisman G (1998) Regeneration of adult rat corticospinal axons induced by transplanted olfactory ensheathing cells. J Neurosci 18(24):10514–10524
Lima C, Escada P, Pratas-Vital J et al (2010) Olfactory mucosal autografts and rehabilitation for chronic traumatic spinal cord injury. Neurorehabil Neural repair 24(1):10–22
Das A, Sribnick EA, Wingrave JM et al (2005) Calpain activation in apoptosis of ventral spinal cord 4.1 (VSC4.1) motoneurons exposed to glutamate: calpain inhibition provides functional neuroprotection. J Neurosci Res 81(4):551–562
Ray SK, Wilford GG, Matzelle DC, Hogan EL, Banik NL (1999) Calpeptin and methylprednisolone inhibit apoptosis in rat spinal cord injury. Ann N Y Acad Sci 890:261–269
Teng YD, Choi H, Onario RC et al (2004) Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci USA 101(9):3071–3076
Wu KL, Hsu C, Chan JY (2009) Nitric oxide and superoxide anion differentially activate poly(ADP-ribose) polymerase-1 and Bax to induce nuclear translocation of apoptosis-inducing factor and mitochondrial release of cytochrome c after spinal cord injury. J Neurotrauma 26(7):965–977
Gensel JC, Tovar CA, Bresnahan JC, Beattie MS (2012) Topiramate treatment is neuroprotective and reduces oligodendrocyte loss after cervical spinal cord injury. PLoS ONE 7(3):e33519
Kumru H, Kofler M (2012) Effect of spinal cord injury and of intrathecal baclofen on brainstem reflexes. Clin Neurophysiol 123(1):45–53
Rong W, Wang J, Liu X et al (2012) 17beta-estradiol attenuates neural cell apoptosis through inhibition of JNK phosphorylation in SCI rats and excitotoxicity induced by glutamate in vitro. Int J Neurosci 122(7):381–387
Garcia-Zozaya IA (2006) Adrenal insufficiency in acute spinal cord injury. J Spinal Cord Med 29(1):67–69
Samantaray S, Matzelle DD, Ray SK, Banik NL (2010) Physiological low dose of estrogen-protected neurons in experimental spinal cord injury. Ann N Y Acad Sci 1199:86–89
Ji B, Li M, Wu WT, Yick LW et al (2006) LINGO-1 antagonist promotes functional recovery and axonal sprouting after spinal cord injury. Mol Cell Neurosci 33(3):311–320
Acknowledgments
Completion of this project was made possible by funding from the National Institutes of Neurological Disorders and Stroke (NS-31622, NS-38146, and NS-41088), the South Carolina Spinal Cord Injury Research Fund (SCSCIRF), and Department of Neurosciences (Neurosurgery). Authors thank Casey Holmes for help with the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Varma, A.K., Das, A., Wallace, G. et al. Spinal Cord Injury: A Review of Current Therapy, Future Treatments, and Basic Science Frontiers. Neurochem Res 38, 895–905 (2013). https://doi.org/10.1007/s11064-013-0991-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11064-013-0991-6